In colorectal cancer, KIF18B has been observed to interact with SP1, resulting in the upregulation of PARPBP and the maintenance of oxaliplatin resistance in oxaliplatin-resistant colorectal cancer (OR-CRC) cells (Hong et al., 2021). Here, KIF18B is linked to colorectal cancer.